15945001

Source:http://linkedlifedata.com/resource/pubmed/id/15945001

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0036043, umls-concept:C0087093, umls-concept:C0205195, umls-concept:C0231441, umls-concept:C0443218, umls-concept:C0937917, umls-concept:C2827483
pubmed:issue	3
pubmed:dateCreated	2005-6-9
pubmed:abstractText	To determine the efficacy and safety of bimatoprost given every evening versus the dorzolamide/timolol fixed combination (DTFC) given twice daily in open-angle glaucoma and ocular hypertensive patients.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9110772
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Amides, http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents, http://linkedlifedata.com/resource/pubmed/chemical/Cloprostenol, http://linkedlifedata.com/resource/pubmed/chemical/Lipids, http://linkedlifedata.com/resource/pubmed/chemical/Ophthalmic Solutions, http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides, http://linkedlifedata.com/resource/pubmed/chemical/Thiophenes, http://linkedlifedata.com/resource/pubmed/chemical/Timolol, http://linkedlifedata.com/resource/pubmed/chemical/bimatoprost, http://linkedlifedata.com/resource/pubmed/chemical/dorzolamide
pubmed:status	MEDLINE
pubmed:issn	1120-6721
pubmed:author	pubmed-author:BaHH, pubmed-author:BeischelC JCJ, pubmed-author:JenkinsJ NJN, pubmed-author:SharpeE DED, pubmed-author:StewartJ AJA, pubmed-author:StewartW CWC
pubmed:issnType	Print
pubmed:volume	15
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	336-42
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:15945001-Amides, pubmed-meshheading:15945001-Antihypertensive Agents, pubmed-meshheading:15945001-Circadian Rhythm, pubmed-meshheading:15945001-Cloprostenol, pubmed-meshheading:15945001-Cross-Over Studies, pubmed-meshheading:15945001-Double-Blind Method, pubmed-meshheading:15945001-Drug Therapy, Combination, pubmed-meshheading:15945001-Female, pubmed-meshheading:15945001-Follow-Up Studies, pubmed-meshheading:15945001-Glaucoma, Open-Angle, pubmed-meshheading:15945001-Humans, pubmed-meshheading:15945001-Intraocular Pressure, pubmed-meshheading:15945001-Lipids, pubmed-meshheading:15945001-Male, pubmed-meshheading:15945001-Middle Aged, pubmed-meshheading:15945001-Ocular Hypertension, pubmed-meshheading:15945001-Ophthalmic Solutions, pubmed-meshheading:15945001-Prospective Studies, pubmed-meshheading:15945001-Safety, pubmed-meshheading:15945001-Sulfonamides, pubmed-meshheading:15945001-Thiophenes, pubmed-meshheading:15945001-Timolol, pubmed-meshheading:15945001-Tonometry, Ocular, pubmed-meshheading:15945001-Treatment Outcome, pubmed-meshheading:15945001-Visual Acuity
pubmed:articleTitle	Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination.
pubmed:affiliation	Omni Eye Services, Atlanta, GA, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study